(vianews) - the market ended the session with erytech pharma (eryp.pa) jumping 11.44% to €0.76 on friday, after four sequential sessions in a row of losses. cac 40 dropped 1.43% to €6,925.40, following the last session's upward trend on what was an all-around negative trend trading session today.
erytech pharma's last close was €0.68, 69.82% under its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-3.99.
revenue growth
year-on-year quarterly revenue growth declined by 58.5%, now sitting on 2.2m for the twelve trailing months.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, erytech pharma's stock is considered to be overbought (>=80).
yearly top and bottom value
erytech pharma's stock is valued at €0.76 at 21:30 est, way below its 52-week high of €2.26 and way above its 52-week low of €0.29.
more news about erytech pharma (eryp.pa).